期刊语言：英语

出版地区：美国

万维提示

1、投稿方式：在线投稿。

2、期刊网址：https://www.heartrhythmjournal.com/

https://www.journals.elsevier.com/heart-rhythm

3、投稿网址：https://www.editorialmanager.com/jhrm

4、期刊刊期：月刊，一年出版12期。

2021年5月25日星期二

投稿须知【官网信息】

Guide for Authors

Heart Rhythm provides rapid online electronic (3-5 business days) and print publication of the most important current scientific developments in the field of cardiac arrhythmias and electrophysiology. The Journal publishes both clinical and basic original, peer-reviewed articles devoted to the diagnosis and treatment of heart rhythm disorders, as well as the electrophysiology of the heart and blood vessels, including ion channels and biophysics, pharmacology, genetics, modeling, cellular and in vivo electrophysiology, outcomes, health systems and health delivery research. In general, review articles are invited, but unsolicited submissions will be considered. All articles are peer-reviewed. Articles from the Editor's institution are processed by a guest editor.

Manuscripts must be submitted online at https://www.editorialmanager.com/jhrm

Ethics in publishing

Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.

Conflict of interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there are no conflicts of interest then please state this: 'Conflicts of interest: none'. See also https://www.elsevier.com/conflictsofinterest. Further information can be found at: https://service.elsevier.com/app/answers/detail/a_id/286/supporthub/publishing.

The corresponding author must upload a signed Heart Rhythm conflict of interest form and include the conflicts of all authors on the title page of the article. The Heart Rhythm conflict form can be found at the following link: https://www.editorialmanager.com/jhrm.

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

Please confirm in the cover letter with your submission that the manuscript is original and that all authors are responsible for the contents and have read and approved the manuscript for submission to Heart Rhythm.

Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

Authorship

All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

Changes to authorship

This policy concerns the addition, deletion, or rearrangement of author names:

Before an article is accepted for publication: If an author is removed or the author order has changed during any revision stage, the corresponding author must upload with the resubmission a letter explaining (a) the reason the person is being removed or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the removal or rearrangement. In the case of removal of authors, this includes confirmation from the author being removed. All documentation should be collated into a single file (preferably PDF) and uploaded via the submission site as an "Author Change Documentation" submission item.

After acceptance, but before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Managing Editor from the corresponding author and include the same information as above. Requests that are not sent by the corresponding author will be forwarded by the Managing Editor to the corresponding author. Note that: (1) Managing Editors will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue must be sent to the Journal Manager and follow the same policies as noted above; changes will result in a corrigendum.

Clinical trial results

In line with the position of the International Committee of Medical Journal Editors, the journal will not consider results posted in the same clinical trials registry in which primary registration resides to be prior publication if the results posted are presented in the form of a brief structured (less than 500 words) abstract or table. However, divulging results in other circumstances (e.g., investors' meetings) is discouraged and may jeopardise consideration of the manuscript. Authors should fully disclose all posting in registries of results of the same or closely related work.

Registration of clinical trials

Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with International Committee of Medical Journal Editors (ICMJE, http://www.icmje.org) recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioral treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

Note that registering drug and biologics trials that are phase II – IV controlled investigations of a product subject to FDA regulation, and device trials including controlled trials of health outcomes of devices subject to FDA regulation, has become mandatory for trials started later than 12/26/07, or 21 days after the first patient is enrolled. Exceptions are for trials ongoing as of 9/27/07 that do NOT involve serious or life threatening conditions; they may be submitted by 9/27/08. For example, all cardiology studies will be considered “serious conditions”. Trials involving serious conditions and initiated before 9/27/07 but completed prior to 12/26/07 are NOT subject to the new requirements. For any questions, consult: http://prsinfo.clinicaltrials.gov; http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-014.html

Article transfer service

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. More information.

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.

Author rights

As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Elsevier supports responsible sharing

Find out how you can share your research published in Elsevier journals.

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Open access

Please visit our Open Access page for more information.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's Author Services.

Informed consent and patient details

Studies on patients or volunteers require Institutional Review Board (IRB) approval, which must be documented in the Methods section of the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author and copies of the consents or evidence that such consents have been obtained must be provided to Elsevier on request. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals, https://www.elsevier.com/patient-consent-policy. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

Animal studies

Animal Studies must conform to the Guide for the Care and Use of Laboratory Animals. Authors must include a statement in the Methods section confirming that the study conforms to these guidelines and was approved by the Institutional Animal Care and Use Committee (IACUC) at the authors' institution.

Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article

Please submit your article via https://www.editorialmanager.com/jhrm.

Revision policy

Revised manuscripts must be received within 6 months of notification of a decision. After this timeframe, any revised paper must be submitted to the journal as a new submission.

Manuscript categories

Original Clinical or Original Experimental

Original research articles must not exceed 5000 words. The word count includes all text in the submission, i.e., title page, keywords, abstract, main text, references, acknowledgments, funding, tables, and figure legends; articles are limited to a combined total of 8 figures and/or tables and 35 references. The abstract (250 words or fewer) is required and should be divided into the following 5 subsections: Background, Objective, Methods, Results, and Conclusion.

Case Reports

Submissions are limited to 6 authors and 2500 words, including text, references (≤15), figure legends, and ≤3 figures. No abstract should be included. All case reports will be considered. Selection priority will be based upon the reporting of new therapies, new complications of therapies, or new mechanisms of diseases.

Contemporary Reviews (Solicited and Unsolicited)

Review articles should include a brief abstract and <6000 total words, including references, and tables; the combined figure/table limit is 8.

Creative Concepts

Submissions to this section are for articles that contain untested or unproven new ideas with little supporting evidence but must have compelling rationale. The idea should be one that is difficult or impossible to test definitively, or would take a long time or significant resources to do so. Articles must be <4000 total words, including references and tables, and a combined total of 8 figures and/or tables. No abstract should be included.

Unknown of the Month

Manuscripts are limited to 1000 words, ≤2 illustrations, ≤4 authors, and ≤5 references. The intracardiac electrograms or electrocardiogram should be presented as an unknown. The figures must contain enough information for the reader to make the correct diagnosis. The figure legends should not reveal the correct diagnosis. The cases will be judged based on degree of difficulty, novelty, and teaching value. No abstract should be included.

……

更多详情：

https://www.elsevier.com/journals/heart-rhythm/1547-5271/guide-for-authors